GleamWall
中文EN

MDWD MediWound Ltd. IFRS

Medicinal Chemicals & Botanical Products · Nasdaq · SEC CIK 1593984 · Fiscal year ends 12/31

Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY-16.1%
TTM net income YoY21.0%
TTM EPS YoY30.7%
Revenue 3-yr CAGR-13.8%
Net income 3-yr CAGR—

Margins

Gross margin19.2%
Operating margin-149.0%
Net margin-140.8%
FCF margin-127.5%
EBITDA margin-145.5%

Returns

ROE-63.9%
ROA-29.9%
ROIC (approx.)-65.6%
Asset turnover0.21x

Leverage & solvency

Liabilities / assets49.4%
Debt / equity0.00x
Current ratio2.33x
Interest coverage-10.27x

Cash quality & payout

Operating cash flow / net income0.68x
Accruals ratio-9.7%
Payout ratio—
Capex / revenue32.5%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY2025*2025-12-31FY2024*2024-12-31
Income statement
Revenue$16.96M$20.22M
Cost of revenue$13.71M$17.59M
Gross profit$3.25M$2.63M
R&D expense$14.32M$8.88M
SG&A expense$8.45M$8.20M
Operating income-$25.27M-$19.40M
Interest expense$2.46M$12.81M
Pretax income-$23.71M-$30.16M
Income tax$169,000$61,000
Net income-$23.88M-$30.22M
EBITDA-$24.68M-$18.77M
EPS (basic)-2.10-3.03
EPS (diluted)-2.10-3.03
Weighted avg. shares (diluted)11.38M9.96M
Balance sheet
Cash & equivalents$4.80M$9.15M
Short-term investments$48.34M$34.01M
Receivables$1.62M$4.80M
Inventory$4.09M$2.69M
Current assets$59.96M$52.16M
PP&E, netmay include right-of-use assets (IFRS)$18.64M$14.13M
Intangibles$33,000$99,000
Total assets$86.25M$73.50M
Current liabilities$25.71M$26.54M
Total liabilities$42.62M$42.34M
Shareholders' equity$43.63M$31.15M
Shares outstanding12.84M10.79M
Cash flow statement
Operating cash flow-$16.12M-$13.62M
Capital expenditure$5.50M$6.27M
Free cash flow-$21.63M-$19.90M
Investing cash flow-$17.95M-$8.40M
Financing cash flow$29.62M$19.39M
Depreciation & amortization$591,000$630,000
Stock-based compensation$3.11M$3.14M

Free plan shows the latest 2 periods; Pro shows all 11 🔒

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.